Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? Read more about Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Read more about Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief. Read more about Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Read more about Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression.
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. Read more about Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid.
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. Read more about Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. Read more about Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection. Read more about Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. Read more about Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. Read more about Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects.
